GlaxoSmithKline Pharma Slips On Q3 Miss [08-02-2022]

Shares of GlaxoSmithKline Pharmaceuticals Ltd. shed over 2.5%, the steepest fall inover a week afterthe company reported net income forthe third quarter that missedthe average analyst estimate, for the quarter-ended December.

GlaxoSmithKline Pharmaceuticals Q3FY22 (Consolidated, YoY)

  • Revenue up 3% at Rs 815.92 crore Vs Bloomberg consensus estimate of Rs 927 crore
  • Net profit down 4% at Rs 150.35 crore Vs estimate of Rs 164 crore
  • Ebitda up 9% at Rs 197.81 crore Vs Rs 180.66 crore
  • Margin at 24.2% Vs 22.8%

Of the nine analysts tracking the company, five maintain ‘buy’, one suggest ‘hold’ and three recommend ‘sell’. The overall consensus price of analysts tracked by Bloomberg imply an upside of 12.7%.

ICICI Securities

  • Maintains ‘reduce’ with the target price cut to Rs 1,498 from Rs 1,564 earlier; implied return of -2.77%.
  • Strong performance in anti-infective, analgesic and VMN segments was offset by weak performance in vaccines segment.
  • Expects recovery in vaccine business to be gradual.
  • Profitability improved due to transfer of Iodex and Ostocalcium brands to GSK Asia Pvt.
  • Expects GSK Pharma to report strong growth in both revenue and earnings in FY22E with healthy recovery in the acute segment and low base.
  • Current valuation already captures all near-term upsides.
  • Healthy growth in newly launched products like Fluarix Tetra and Menveo augurs well for the future growth.

Motilal Oswal

  • Maintains ‘neutral’ with the target price raised to Rs 1,630 from Rs 1,600 earlier; an implied return of 3.13%
  • Growth in pharma portfolio was offset by lower off-take of vaccines because of the third covid wave.
  • Expects gradual revival in the vaccine business.
  • Expects 10% earnings CAGR over FY22-24, led by healthy brand recall in pharma portfolio and recovery in vaccine sales.
  • Tweaks EPS estimates for FY22/FY23/FY24 by 2% to factor in improved outlook for vaccine business, better traction in brands like Augmentin/Ceftum and removal of sales of brands transferred to GSK Asia.
  • Current valuation adequately factors in the upside from potential revenue growth.

सोशल मीडिया अपडेट्स के लिए हमें
Facebook ( )
linkedin ( )
और Twitter ( ) पर फॉलो करें।

हमारी फ्री सर्विस और लोगो की paid सर्विस से कई गुना अच्छी है।
आपको हर दिन दिए जाएंगे 3 से 5 कॉल बिलकुल फ्री
हर CALL में PROFIT दिये जायेंगे
तो जल्दी से MCX CHANNEL को JOIN कर लो


Adani Won’t Seek Compensatory Tariff From India’s Gujarat State

Billionaire Gautam Adani’s group firm Adani Power Mundra Ltd. and western Indian state of Gujarat have settled a dispute over compensatory tariff dues, India’s Attorney General KK Venugopal said at a hearing in Supreme Court.

  • Adani Power will resume power supply to Gujarat and forgo the higher tariff earlier claimed as compensation for increased price of imported coal, Venugopal said.
  • Supreme Court disposed of the case that had sought a relook at 2019 verdict of the court, and said the two parties will be governed by the settlement terms.

Source: Bloomberg

Spread the love

Neal Bhai has been involved in the Bullion and Metals markets since 1998 – he has experience in many areas of the market from researching to trading and has worked in Delhi, India. Mobile No. - 9899900589 and 9582247600

Leave a Comment